Drug products: Allgil, Crominet, Lecrolyn, Lecrolyn sine, Lomudal Nasal, Lomudal®, Lomudal® Nasal, Lomusol Nasal, Natriumkromoglikat ABECE, Pollicrom, Pollyferm®
ATC code: R01AC01, S01GX01
Published controlled studies on differences between men and women regarding pharmacokinetics, dosing and safety of sodium cromoglycate are lacking. The effect of sodium cromoglycate as a treatment for improving tear film break up time was in a small study shown to be better in women.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.
No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of sodium cromoglycate have been found.
In a randomized study of sodium cromoglycate’s prolonging effect of tear film break up time in patients with an [abnormal tear film break-up] acute tear film break up phenomenon (13 men, 28 women) men had a lower increase in mean tear film break up time than women (39% vs 83%) . Women have been shown to have a higher concentration of magnesium ions in their tear fluid . A hypothesis to explain the better effect is that magnesium ions in tear fluid induce gelling of sodium cromoglycate thus creating a protective film .
No studies with a clinically relevant sex analysis regarding the adverse effects of sodium cromoglycate have been found.
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2015-10-21
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson